Canadian Lung Association   Report issue

Foundation Phase 2 Phase 3 Phase 4
Founded: Ottawa Canada (1900)

Organization Overview

First Clinical Trial
2002
NCT00876356
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Canadian Lung Association | Canadian Lung Association/British Columbia Lung Association | Lung Association of Saskatchewan | Ontario Lung Association

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alcoholism (Phase 4)

Asthma (Phase 2)

Coinfection (Phase 3)

Communicable Diseases (Phase 3)

Dyspnea (Phase 4)

HIV Infections (Phase 3)

Infections (Phase 3)

Lung Diseases, Obstructive (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Tobacco Use Disorder (Phase 2)

Tuberculosis (Phase 3)

Tuberculosis, Pulmonary (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial APIs: 11